Cargando…

Phase I study on docetaxel and ifosfamide in patients with advanced solid tumours.

Docetaxel and ifosfamide have shown significant activity against a variety of solid tumours. This prompted a phase I trial on the combination of these drugs. This phase I study was performed to assess the feasibility of the combination, to determine the maximum tolerated dose (MTD) and the side effe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pronk, L. C., Schrijvers, D., Schellens, J. H., de Bruijn, E. A., Planting, A. S., Locci-Tonelli, D., Groult, V., Verweij, J., van Oosterom, A. T.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1998
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2151260/ https://www.ncbi.nlm.nih.gov/pubmed/9459161

Ejemplares similares

A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours
por: Pronk, L C, et al.
Publicado: (2000)

Phase 1 study on docetaxel and ifosfamide in patients with advanced solid tumours
Publicado: (1998)

Phase I study of docetaxel plus ifosfamide in patients with advanced cancer
por: Marx, G, et al.
Publicado: (2002)

Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
por: González-Manzano, R., et al.
Publicado: (1995)

Phase I/II study of a short course of weekly cisplatin in patients with advanced solid tumours.
por: Planting, A. S., et al.
Publicado: (1993)

Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitinib and ifosfamide in patients with advanced solid malignancies
por: Hamberg, P, et al.
Publicado: (2010)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours.
por: Schellens, J. H., et al.
Publicado: (1996)

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
por: Attard, G, et al.
Publicado: (2007)

Possible metabolic interaction between docetaxel and ifosfamide
por: Ando, Y
Publicado: (2000)

Phase I–II study of docetaxel and ifosfamide combination in patients with anthracycline pretreated advanced breast cancer
por: Kosmas, C, et al.
Publicado: (2003)

Phase I study of axitinib combined with paclitaxel, docetaxel or capecitabine in patients with advanced solid tumours
por: Martin, L P, et al.
Publicado: (2012)

Pazopanib exposure decreases as a result of an ifosfamide-dependent drug–drug interaction: results of a phase I study
por: Hamberg, P, et al.
Publicado: (2014)

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks
por: Kerbusch, T, et al.
Publicado: (2004)

A phase I trial of ispinesib, a kinesin spindle protein inhibitor, with docetaxel in patients with advanced solid tumours
por: Blagden, S P, et al.
Publicado: (2008)

A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
por: Bowles, D W, et al.
Publicado: (2013)

A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2014)

A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study
por: Fokkema, E, et al.
Publicado: (2000)

A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance.
por: Verweij, J., et al.
Publicado: (1991)

Phase I dose-escalation study of aflibercept in combination with docetaxel and cisplatin in patients with advanced solid tumours
por: Freyer, G, et al.
Publicado: (2012)

Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature
por: Pelgrims, J, et al.
Publicado: (2000)

Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
por: Gerrits, C. J., et al.
Publicado: (1996)

Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects.
por: Klijn, J. G., et al.
Publicado: (1990)

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck
por: Couteau, C, et al.
Publicado: (1999)

Phase I and pharmacological study of pazopanib in combination with oral topotecan in patients with advanced solid tumours
por: Kerklaan, B Milojkovic, et al.
Publicado: (2015)

A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours
por: Rasschaert, M, et al.
Publicado: (2007)

Isophosphoramide mustard, a metabolite of ifosfamide with activity against murine tumours comparable to cyclophosphamide.
por: Struck, R. F., et al.
Publicado: (1983)

Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2005)

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours
por: Boss, D S, et al.
Publicado: (2012)

A Phase II Study of Docetaxel in Patients with Relapsed and Refractory Ewing's Tumours
por: Meyer, T., et al.
Publicado: (2003)

Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin.
por: Hilkens, P. H., et al.
Publicado: (1997)

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
por: Ang, Yvonne L. E., et al.
Publicado: (2020)

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
por: Eskens, F A L M, et al.
Publicado: (2008)

A phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumours
por: Paridaens, R, et al.
Publicado: (2000)

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients.
por: Bakker, M., et al.
Publicado: (1998)

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306
por: Tanaka, Kazuhiro, et al.
Publicado: (2022)

The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.
por: Bokemeyer, C., et al.
Publicado: (1994)

A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours
por: Wachters, F M, et al.
Publicado: (2004)

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial
por: Ernst, T, et al.
Publicado: (2007)

The growing pains of ifosfamide
por: Sprangers, Ben, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3445gk0vo1aob9hj086f7g3o77